4BB9587B-88CB-4BD9-BE1D-2CDF61337579
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 46.9119579500657
- age_years
- 22
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.630
- MYC_TARGETS_V1+0.595
- NOTCH_SIGNALING+0.525
- G2M_CHECKPOINT+0.523
- WNT_BETA_CATENIN_SIGNALING+0.507
- E2F_TARGETS+0.497
- UNFOLDED_PROTEIN_RESPONSE+0.472
- TGF_BETA_SIGNALING+0.467
- INTERFERON_ALPHA_RESPONSE+0.439
- DNA_REPAIR+0.429
Top 10 suppressed
- KRAS_SIGNALING_DN-0.446
- SPERMATOGENESIS-0.275
- MYOGENESIS-0.223
- PANCREAS_BETA_CELLS-0.165
- BILE_ACID_METABOLISM-0.158
- XENOBIOTIC_METABOLISM-0.060
- ESTROGEN_RESPONSE_LATE-0.043
- APICAL_SURFACE-0.042
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.035
- COAGULATION+0.011
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | AB522ACF-5D84-41B0-9671-CE2511EBD94F | — | — | 0.942 |
| 2 | 745233F1-DF41-4DDA-9146-1666DD59355E | — | — | 0.926 |
| 3 | SRR934861 | — | — | 0.924 |
| 4 | SRR934827 | — | — | 0.924 |
| 5 | 55E3F1FB-D55D-42F8-A9E1-7828F7BFF595 | — | — | 0.919 |
| 6 | F226F6D3-DE88-4B15-A0F1-63EDB55E8F9D | — | — | 0.919 |
| 7 | 63E967C4-863F-4253-ADFE-3CDC13B6187A | — | — | 0.914 |
| 8 | 6A30D8D0-DDB8-4B34-8BCB-46986144F551 | — | — | 0.914 |
| 9 | SRR934719 | — | — | 0.913 |
| 10 | A4821960-9921-4B07-98CE-C4FDCA15146D | — | — | 0.912 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 41 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.630 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.595 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.525 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.523 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.507 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.497 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.472 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.467 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.439 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.429 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.358 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.350 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.348 | Remibrutinib | — uncovered |
| ANGIOGENESIS | 0.347 | Remibrutinib | — uncovered |
| MTORC1_SIGNALING | 0.339 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.334 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.271 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.269 | Inavolisib | — uncovered |
| APOPTOSIS | 0.262 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.243 | Inavolisib | — uncovered |